Study Evaluating Liver Transplantation in Haemophilia Patients in Spain

Wyeth is now a wholly owned subsidiary of Pfizer11 enrolled

Overview

This study will analyze survival and outcome of patients with severe haemophilia who undergo liver transplantation in Spain

Probability Sample

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hemophilia Hemophilia B

Interventions

Epidemiological Non interventionalOTHER

Epidemiological Non interventional

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with haemophilia who underwent liver transplantation and who have been followed-up at any site in Spain. Exclusion Criteria: * Patients without informed consent form.

Outcomes

Primary Outcomes

Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation

Cyclosporine, corticosteroids, tacrolimus, mycophenolate mofetil, everolimus were considered as immunosuppressive therapy after liver transplantation.

Time frame: Post liver transplantation up to Month 3

Number of Participants With Acute Rejection of Liver Transplant

Any acute rejection of the liver transplant was clinically suspected and biopsy proven by central pathologist.

Time frame: Post liver transplantation up to Month 3

Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation

Number of participants who had liver transplantation after cirrhosis due to hepatitis C virus (HCV) infection and experienced recurrence of HCV infection post liver transplantation.

Time frame: Post liver transplantation up to Month 3

Number of Participants Who Survived After Liver Transplantation

Number of participants who survived after liver transplantation was reported. The death reported was a result of acute-related transplantation complications and end-stage liver disease.

Time frame: Post liver transplantation up to Month 3

Secondary Outcomes

Number of Participants Requiring Exogenous Clotting Factor Infusion During Liver Transplantation

Exogenous clotting factors administered post liver transplant included Prothromplex; platelets, fibrinogen and fresh frozen plasma (FFP) combination; FFP and platelets combination. Clotting factors were administered either as bolus or as continuous infusion.

Time frame: Up to Day 5 post liver transplantation

Dose of Exogenous Clotting Factors Used During Liver Transplantation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.